Clinical trials: Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)
- Condition Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)
- Funder type Industry (pharma, biotech, devices)
Coronary Artery Disease, Stable Angina
Validation of the MedHub AutocathFFR Software Device for Non-Invasive Fractional Flow Reserve (FFR)
This observational study evaluated how well the AutocathFFR software measures fractional flow reserve (FFR) from coronary angiogram images.
- Conditions
- Coronary Artery Disease, Stable Angina, Unstable Angina, Non-ST-Elevation Myocardial Infarction
- Trial name
- NCT07763769
- Testing
- MedHub AutocathFFR
- Where
- 4 sites in United States
- Volunteers
- 277 people
- Sponsor
- Medhub Ltd.
Coronary Artery Diseases
BIOFLOW III Satellite-Italy Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). 500 subjects will be enrolled in this registry.
- Trial name
- NCT02028728
- Where
- 18 sites in Italy
- Volunteers
- 609 people
- Sponsor
- Biotronik Italia S.p.A.
Cost Sharing, Acute Coronary Syndrome
Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication, patient adherence, and clinical outcomes.
- Trial name
- ARTEMIS (NCT02406677)
- Testing
- Study voucher card
- Where
- 272 sites in United States, Puerto Rico
- Volunteers
- 11,001 people
- Sponsor
- AstraZeneca
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Israel Satellite Registry
BIOTRONIK - SaFety and Performance Registry for a diabetic patient population with the .bimus Eluting Orsiro Stent System Within daily clinical practice - III
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Diabetes Mellitus Type 1 or 2
- Trial name
- NCT01895712
- Where
- 6 sites in Israel
- Volunteers
- 120 people
- Sponsor
- BIOTRONIK Israel
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Belgium Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT01831336
- Where
- 8 sites in Belgium
- Volunteers
- 332 people
- Sponsor
- Biotronik Belgium NV
Acute Coronary Syndromes
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
While troponin is not detectable until several hours after an Acute Myocardial Infarction (AMI), copeptin is expected to be elevated very early after an AMI.
- Trial name
- CHOPIN (NCT00952744)
- Where
- 11 sites in United States
- Volunteers
- 2,071 people
- Sponsor
- Brahms AG
Acute Coronary Syndrome, Myocardial Infarction
Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)
The purpose of the COGENT-1 clinical trial is to determine whether CGT-2168 (clopidogrel and omeprazole) compared to clopidogrel is safe and effective in reducing the incidence of gastrointestinal bleeding and symptomatic ulcer…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- COGENT-1 (NCT00557921)
- Testing
- CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
- Where
- 491 sites in United States, Australia and 14 more
- Volunteers
- 5,000 people
- Sponsor
- Cogentus Pharmaceuticals
Acute Non-ST Elevation Myocardial Infarction
DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization
This is a prospective, randomized, double-blind, double-dummy, and controlled study of DLBS1033 in the management of acute non-ST elevation myocardial infarction (NSTEMI) without early coronary revascularization.
- Trial name
- NCT02146664
- Testing
- DLBS1033
- Where
- 2 sites in Indonesia
- Sponsor
- Dexa Medica Group
Non-ST Segment Elevation Myocardial Infarction
Anfibatide Phase Ib-IIa Clinical Trial
Investigate the safety and efficacy of Anfibatide in non-ST segment myocardial infarction patients
- Trial name
- NCT01585259
- Testing
- Anfibatide
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Lee's Pharmaceutical Limited
Coronary Artery Disease
SELUTION 4 De Novo Small Vessel IDE Trial
Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as…
- Trial name
- NCT05946629
- Testing
- PCI with SELUTION SLR DCB, PCI with FDA approved "-limus" DES
- Where
- 70 sites in United States, Belgium and 1 more
- Volunteers
- 960 people
- Sponsor
- M.A. Med Alliance S.A.
STEMI, NSTEMI
Assessment of Individual Risk of Cardiovascular Events by Platelet FcGammaRIIa
This is a Prospective, Observational Multicenter Non-Interventional Cohort Study. The primary objective is to determine whether platelet expression of FcγRIIa is associated with risk of myocardial infarction (MI), stroke and…
- Trial name
- NCT05175261
- Testing
- Prolocor pFCG test
- Where
- United States
- Volunteers
- 764 people
- Sponsor
- Prolocor, Inc
ACS - Acute Coronary Syndrome, NSTEMI - Non-ST Segment Elevation MI
MCG Discovery Study in Emergency Departments
This prospective discovery study is designed to demonstrate the feasibility of using an unshielded, mobile MCG device in an Emergency Department (ED) setting.
- Trial name
- NCT06095557
- Testing
- Sponsor MCG device
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- SB Technology, Inc.